Also in this playlist...
This transcript is automatically generated
Or John or -- actually -- money back at a -- -- -- if this goes forward are you willing to do that are you willing to take money off the table maybe.
Slowdown drug development if you do get a negative message from -- -- administration.
I right now what I can point to is history.
And I think as we've seen in Europe over the last twenty to thirty years price controls and access restrictions come into play.
It is greatly dampened R&D investment in Europe.
I think if you go back and look at the Clinton health care plan in the early ninety's there's no question that what you saw out of that.
Was lowered deep -- are -- spending by the companies and our industry.
That's only playing out now those -- the investments we didn't make then for the drugs that never came twelve years later.
Tell me about your experiences you've had a few.
What's -- been out for years or so since -- Medicare part.
Has kicked in what has that done differently for Eli -- -- the Medicare prescription plan first of all been a huge success.
This -- a program that has come in way under budget compared to what it -- originally forecast you have competition.
For patients across the country.
And the most recent data I've seen from seniors a month ago says that eighty to 90% of them are pleased with their access the availability of -- I think what it means for Lilly and other companies this industry is that people that need our products are able to get our products.
John let's talk business now I want to ask you this a lot of speculation out there that you may be making a bid for Amylin Pharmaceuticals can you comment on that.
I've been very clear I've been asked this question constantly.
And I don't know how else to say here all that there's no truth to that.
We like her -- and relationship just the way it is.
They have what has a number of issues they're working through with their shareholders right now what we're focused on what -- -- -- try to sell or buy it -- I had -- -- -- question let's look at the stock that looked like a -- at the company you know five years ago you were at 75 bucks a share well off that now you're you're down.
Bid is stock -- and we're showing our viewers analyst you don't want to -- Amylin but Eli Lilly your shareholders in the thirty dollar range L.
What do you say to your shareholders with that are probably nervous.
With a -- dividend paying stocks like yours they're nervous about what Obama is trying to do -- what do you say to them.
Well first of all -- point -- the fact that I believe -- society we're going to continue to need and want innovation.
There's really no effective treatment for alzheimer's they were gonna have to molecules in phase three this year for alzheimer's.
We're all worried about cancer we see only incremental progress being made there.
I think we're we're on the verge of a huge opportunity what I look at our scientific Discovery Labs the question is.
That we build an eco system and can we come up with government policies that will help us to really realize the potential benefits that are out there.
All right for all the -- in -- in addition to that -- you've got take a broad range of products one other area it would be your.
Future would have beat the cancer would -- -- the sexual impotence of C Alice product that you have -- BV a mental -- there W dot all those areas under your.
-- I think for us it's pretty clear looking forward oncology or cancer treatments going to be part of our sweet spot BM clone acquisition.
Last October I think -- that.
Diabetes and cardiovascular disease are gonna continue to be important for us we're still awaiting the FDA approval of F yet.
We recently launched that that cardiovascular product in Europe.
And I think -- you can expect we'll continue to be a strong player neural science as well.
John like whether the chairman -- CEO.
It literally just a pleasure to talk to thank you for talking exclusively to -- business today John do you --
Filter by section